Spectrum Of Activity
Mild or moderate CAPAECB320 mg PO q24h x5-7d320 mg PO q24h x5d
Safety and efficacy in pediatric patients <18y of age have not been established
No dose adjustment
CrCl >40CrCl ≤40CAPDHDCRRTNo dose adjustment160 mg PO q24h160 mg PO q24h160 mg q24h (give dialysis day dose after dialysis)No data
A fluoroquinolone bactericidal drug with a wide-spectrum of activity against Gram-negative and Gram-positive microorganisms
Acute bacterial exacerbation of chronic bronchitis
Black Box Warning:
Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions.
Reserve use of gemifloxacin mesylate for patients with no alternative treatment options for acute bacterial exacerbation of chronic bronchitis.
Avoid in patients with known history of myasthenia gravis.
Monitor fever, CBC, symptomatic improvement.
Prolonged QT interval
Rupture of tendon
- QT interval prolonging drugs
Multiple drug-drug interactions
Antimicrobial class: Fluoroquinolone
Pregnancy category: C
Average serum half life: 7 hours
Increased risk of QT interval prolongation in patients with ongoing proarrhythmic conditions.
Discotninue if hypersensitivity reactions, neurologic effects, and toxic psychosis occur.
Discontinue therapy at first sign of tendon pain, swelling, inflammation, or rupture.
Sensory or sensorimotor axonal polyneuropathy that may be irreversible has been reported; discontinue if symptoms occur.